Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on camrelizumab plus apatinib mesylate as perioperative treatment for resectable hepatocellular carcinoma; the study spans Phase 2 and Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma, Immunotherapy | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING